Justin P.O. Lindemann

AstraZeneca (Netherlands) — Netherlands

Biochemistry, Genetics and Molecular Biology · Life Sciences

28h-index3.5kcitations183works4.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Estrogen and related hormone effects(100), Advanced Breast Cancer Therapies(94), HER2/EGFR in Cancer Research(40), PI3K/AKT/mTOR signaling in cancer(35), PARP inhibition in cancer therapy(19)

Publications183 total

Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study
Journal of Clinical Oncology·2026Open Access
Supplementary Figure S5 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Supplementary Figure S4 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Figure 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Figure 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Table 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Data from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Supplementary Table S2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Supplementary Table S1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Supplementary Figure S2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Table 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Figure 3 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Supplementary Table S3 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Supplementary Table S4 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Supplementary Figure S3 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Supplementary Figure S1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Clinical Cancer Research·2025· 2 citedOpen Access
Abstract PS7-08: Results from SERENA-1 Parts K/L: A Phase 1 study of the next-generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) in combination with ribociclib in women with ER-positive, HER2 negative advanced breast cancer
Clinical Cancer Research·2025
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
The Lancet Oncology·2024· 61 cited
274P A multiomic approach for camizestrant-induced estrogen receptor (ER) degradation, antagonism and anti-proliferation: Exploratory analysis from SERENA-3
Annals of Oncology·2024Open Access
page 1 of 10Next →

Frequent Co-authors

Teresa Klinowska(18), Christopher J. Morrow(14), Andrew Foxley(13), Gaia Schiavon(12), Udai Banerji(12), Mafalda Oliveira(12), Anne Armstrong(12), Rhiannon Maudsley(10), Erika Hamilton(10), Paul Rugman(9), Richard D. Baird(9), Martin Pass(8), Peter Kabos(7), Manish R. Patel(7), José Alejandro Pérez Fidalgo(6), Helen Ambrose(6), J.F.R. Robertson(6), Nicholas C. Turner(6), Alastair Mathewson(6), Tim Brier(6)